
1. j acquir immune defic syndr. 2012 oct 1;61(2):208-15.

a randomized controlled trial tailored group smoking cessation intervention 
for hiv-infected smokers.

moadel ab(1), bernstein sl, mermelstein rj, arnsten jh, dolce eh, shuter j.

author information: 
(1)department epidemiology population health, albert einstein college of
medicine, albert einstein cancer center, bronx, ny, usa.

background: half persons living human immunodeficiency
virus (hiv; plwh) us smoke cigarettes, tobacco use responsible 
considerable morbidity mortality group. little known the
efficacy tobacco treatment strategies plwh.
design: randomized controlled trial comparing positively smoke free (psf), an
intensive group-therapy intervention targeting hiv-infected smokers, standard 
care.
methods: cohort 145 plwh smokers, recruited hiv-care center the
bronx, new york, randomized 1:1 psf program standard care. all
were offered 3-month supply nicotine replacement therapy. psf an
8-session program tailored address needs concerns hiv-infected
smokers. sessions cofacilitated graduate student an
hiv-infected peer. primary outcome biochemically confirmed, 7-day
point-prevalence abstinence 3 months.
results: intention-to-treat analysis, psf condition subjects nearly
double quit rate controls (19.2% vs. 9.7%, p = 0.11). complete
case, as-treated analysis, assignment psf associated increased odds
of quitting (odds ratio(adj) 3.55, 95% confidence interval 1.04 12.0). latino 
ethnicity lower loneliness score predictive abstinence. subjects 
in psf condition exhibited significant decreases daily cigarette
consumption significant increases self-efficacy motivation quit.
attendance â‰¥7 sessions associated higher quit rates.
conclusions: findings suggest positive effect psf cessation rates
in plwh smokers. loneliness self-efficacy influential factors the
smoking behaviors plwh.

doi: 10.1097/qai.0b013e3182645679 
pmcid: pmc3568498
pmid: 22732470  [indexed medline]

